[Value of diuretics and aldosterone antagonists in the treatment of heart failure].
Schwinger
R H
RH
Klinik III für Innere Medizin, Universität zu Köln. Robert.Schwinger@medizin.uni-koeln.de
D001581:Benzothiadiazines; D004232:Diuretics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004347:Drug Interactions; D004351:Drug Resistance; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009399:Nephrons / Q000187:drug effects; D016032:Randomized Controlled Trials as Topic; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013148:Spironolactone / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors
D001581:Benzothiadiazines; D004232:Diuretics; D000451:Mineralocorticoid Receptor Antagonists; D049993:Sodium Chloride Symporter Inhibitors; D013148:Spironolactone